Magazine Article | September 1, 2021

Companies To Watch: AltruBio

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Aiming checkpoint regulators at immune diseases

SNAPSHOT

AltruBio is a private company developing checkpoint-regulator monoclonal antibodies (mAbs) for treating immune disorders. The company uses its checkpoint regulators in a way it believes down-modulates overactivated T cells to restore natural homeostasis in treating autoimmune inflammation of T-cell-associated diseases, such as psoriasis, psoriatic arthritis, ulcerative colitis, multiple sclerosis, Type 1 diabetes, and graft-versus-host disease (GVHD). Most of AltruBio’s development efforts are with neihulizumab (AbGn-168H), a potentially versatile molecule the company has dubbed “a pipeline in a product.” Neihulizumab is in Phase 1b trials for steroid refractory acute GVHD and frontline acute GVHD. A second compound, leiolizumab (AbGn-268), is in preclinical research.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: